Analysts Set Expectations for MRSN Q1 Earnings

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Mersana Therapeutics in a report released on Monday, March 3rd. Leerink Partnrs analyst J. Chang anticipates that the company will earn ($0.17) per share for the quarter. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.15) EPS and Q4 2025 earnings at ($0.14) EPS.

A number of other brokerages have also commented on MRSN. Citigroup assumed coverage on Mersana Therapeutics in a report on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. William Blair assumed coverage on Mersana Therapeutics in a report on Thursday, February 6th. They set an “outperform” rating on the stock. Finally, Wedbush reissued an “outperform” rating and set a $4.00 price target on shares of Mersana Therapeutics in a report on Monday. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $4.25.

Mersana Therapeutics Price Performance

Shares of NASDAQ MRSN opened at $0.48 on Tuesday. Mersana Therapeutics has a 1-year low of $0.48 and a 1-year high of $6.28. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. The business’s fifty day moving average price is $0.84 and its two-hundred day moving average price is $1.57. The firm has a market capitalization of $59.30 million, a PE ratio of -0.79 and a beta of 1.39.

Mersana Therapeutics (NASDAQ:MRSN) last issued its earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The firm had revenue of $16.36 million for the quarter, compared to analyst estimates of $7.71 million.

Hedge Funds Weigh In On Mersana Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of MRSN. US Bancorp DE acquired a new position in shares of Mersana Therapeutics in the 3rd quarter valued at $31,000. Los Angeles Capital Management LLC boosted its position in shares of Mersana Therapeutics by 8.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock valued at $358,000 after purchasing an additional 14,240 shares during the period. GSA Capital Partners LLP boosted its position in shares of Mersana Therapeutics by 368.9% in the 3rd quarter. GSA Capital Partners LLP now owns 271,774 shares of the company’s stock valued at $514,000 after purchasing an additional 213,814 shares during the period. Intech Investment Management LLC acquired a new position in shares of Mersana Therapeutics in the 3rd quarter valued at $52,000. Finally, HealthInvest Partners AB boosted its position in Mersana Therapeutics by 191.3% during the 3rd quarter. HealthInvest Partners AB now owns 538,621 shares of the company’s stock worth $1,018,000 after acquiring an additional 353,721 shares during the period. Institutional investors and hedge funds own 93.92% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.